Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

ET Intelligence Group: Symbiotec Pharmalab plans to raise ₹150 crore through a fresh issue to repay debt and ₹1,607 crore through an offer for sale. The promoter group’s stake will fall to 33.3% after the IPO from 36.4%. The company is engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products.Over two-third of the revenue comes from international markets with Europe contributing nearly 30%. Top five products contribute nearly 63% to revenue, signalling product concentration. The valuation is attractive compared with peers. Given these factors and market leadership in some of the products, investors with high-risk appetite may apply for the long-term.

Business

Incorporated in 2002, Symbiotec Pharmalab has a global leadership position in corticosteroid and steroidal-hormone APIs in volume terms in FY26, with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs According to Frost & Sullivan. It was the only company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in FY26. The company has a backward-integrated platform with approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations. APIs continue to be the primary revenue driver, contributing more than 96% to total revenue in FY26, while newer initiatives such as complex injectables and contract manufacturing (CDMO) offerings make up the balance. As of FY26, the company operated two API manufacturing facilities and commissioned two additional plants, expanding fermentation capacity to 700 KL and adding complex injectables capacity of 20 million vials annually.

Financials

Between FY24 and FY26, revenue from operations grew 10.2% annually to ₹869.1 crore, operating profit before interest, tax, depreciation and amortization (EBITDA) increased 14.5% to ₹232 crore and net profit rose 4.8% to 109.9 crore. While EBITDA margin expanded to 26.6% in FY26 from 24.5% in FY24, operating cash flow remained volatile, rising to ₹174.6 crore in FY26 from ₹47.3 crore in FY25, compared with ₹187.5 crore in FY24. It reflects heavy capital expenditure and fluctuations in working capital, particularly inventory and trade payables.Read more: Pride Hotels steps up expansion, plans Rs 1,000-cr IPO by December

Valuation

Symbiotec lacks an exact listed peer due to a niche in steroidal hormones and advanced drug-device formulation. Considering the post-IPO equity and net profit for FY26, the company demands a price-earnings (P/E) multiple of up to 58. For other API or biotechnology manufacturers such as Concord Biotech, Divi’s Laboratories, Cohance Lifesciences and Laurus Labs, the P/E range is between 63 and 110.